SGH
Sivik Global Healthcare Portfolio holdings
AUM
$224M
This Quarter Return
+1.21%
1 Year Return
+5.3%
3 Year Return
+45.33%
5 Year Return
+103.79%
10 Year Return
+430.94%
AUM
$290M
AUM Growth
+$290M
(-2.8%)
Cap. Flow
-$23.4M
Cap. Flow
% of AUM
-8.06%
Top 10 Holdings %
Top 10 Hldgs %
37.09%
Holding
61
New
12
Increased
15
Reduced
10
Closed
19
Top Buys
| 1 |
Select Medical
SEM
|
$9.97M |
| 2 |
Smith & Nephew
SNN
|
$8.57M |
| 3 |
UnitedHealth
UNH
|
$6.22M |
| 4 |
Becton Dickinson
BDX
|
$6.15M |
| 5 |
HCA Healthcare
HCA
|
$6.07M |
Top Sells
| 1 |
SPDR S&P Biotech ETF
XBI
|
$13.5M |
| 2 |
Universal Health Services
UHS
|
$11M |
| 3 |
Tenet Healthcare
THC
|
$9.69M |
| 4 |
Zimmer Biomet
ZBH
|
$9.65M |
| 5 |
Biogen
BIIB
|
$6.93M |
Sector Composition
| 1 | Healthcare | 99.19% |
| 2 | Energy | 0.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
HCA Healthcare
HCA
$94.5B
| $13.4M | 3.19% |
55,000
+25,000
| +83% | +$6.07M |
|
|
2
Select Medical
SEM
$1.61B
| $13.3M | 3.17% |
200,000
+150,000
| +300% | +$9.97M |
|
3
Johnson & Johnson
JNJ
$427B
| $11.3M | 2.7% |
70,000
+15,000
| +27% | +$2.42M |
|
|
4
Tenet Healthcare
THC
$16.3B
| $11.1M | 2.64% |
80,000
-70,000
| -47% | -$9.69M |
|
|
SGEN
5
DELISTED
Seagen Inc. Common Stock
SGEN
| $10.3M | 2.46% |
39,000
+19,000
| +95% | +$5.01M |
|
|
6
UnitedHealth
UNH
$281B
| $10.2M | 2.45% |
70,000
+42,500
| +155% | +$6.22M |
|
7
Medtronic
MDT
$119B
| $10M | 2.4% |
80,000
| – | – |
|
8
Boston Scientific
BSX
$156B
| $9.55M | 2.28% |
220,000
+30,000
| +16% | +$1.3M |
|
9
Baxter International
BAX
$12.7B
| $9.25M | 2.21% |
115,000
+45,000
| +64% | +$3.62M |
|
10
Danaher
DHR
$147B
| $9.13M | 2.18% |
30,000
| – | – |
|
11
McKesson
MCK
$85.4B
| $8.97M | 2.14% |
45,000
+5,000
| +13% | +$997K |
|
12
Avantor
AVTR
$9.18B
| $8.59M | 2.05% |
210,000
-40,000
| -16% | -$1.64M |
|
|
13
Smith & Nephew
SNN
$16.3B
| $8.57M | 2.05% |
+15,000
| New | +$8.57M |
|
14
IQVIA
IQV
$32.4B
| $8.38M | 2% |
35,000
| – | – |
|
15
Abbott
ABT
$231B
| $8.27M | 1.98% |
70,000
+20,000
| +40% | +$2.36M |
|
16
Charles River Laboratories
CRL
$8.04B
| $8.25M | 1.97% |
20,000
-5,000
| -20% | -$2.06M |
|
|
CTLT
17
DELISTED
CATALENT, INC.
CTLT
| $8.1M | 1.94% |
60,900
-9,100
| -13% | -$1.21M |
|
18
Eli Lilly
LLY
$657B
| $8.09M | 1.93% |
35,000
-5,000
| -13% | -$1.16M |
|
19
Merck
MRK
$210B
| $7.51M | 1.79% |
100,000
+40,000
| +67% | +$3M |
|
20
Encompass Health
EHC
$12.3B
| $7.5M | 1.79% |
100,000
+30,000
| +43% | +$2.25M |
|
21
Globus Medical
GMED
$8.27B
| $7.28M | 1.74% |
95,000
+40,000
| +73% | +$3.06M |
|
22
Labcorp
LH
$23.1B
| $7.04M | 1.68% |
25,000
| – | – |
|
23
Cencora
COR
$56.5B
| $6.87M | 1.64% |
57,500
+7,500
| +15% | +$896K |
|
24
Centene
CNC
$14.3B
| $6.23M | 1.49% |
100,000
-40,000
| -29% | -$2.49M |
|
|
25
Becton Dickinson
BDX
$55.3B
| $6.15M | 1.47% |
+25,000
| New | +$6.15M |
|